Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patiromer - Relypsa

Drug Profile

Patiromer - Relypsa

Alternative Names: ILY-105; Patiromer acetate; Patiromer calcium; Patiromer sorbitex calcium; RLY-105; RLY-5016; RLY-5016S; Veltassa; ZG 801

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Relypsa
  • Developer Otsuka Pharmaceutical; Relypsa; Vifor Fresenius Medical Care Renal Pharma; Zeria
  • Class Polymers
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia

Most Recent Events

  • 06 Mar 2024 Phase-II clinical trials in Hyperkalaemia (In neonates, In infants, In children) in USA (PO) (NCT05766839) (EudraCT2023-505252-21-00) (EudraCT2022-501829-20)
  • 16 Mar 2023 Vifor Pharma plans the phase II EMERALD-2 trial for Hyperkalemia (In children, In infants, In neonates) in USA (PO) (NCT05766839) (EudraCT2022-501829-20)
  • 13 Mar 2023 Zeria Pharmaceutical completes a phase III trial for Hyperkalaemia (In adults, In the elderly) in Japan (PO, Powder) (NCT04955678)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top